The DECs are working in collaboration with industry and academics
to develop innovative approaches to generating evaluation evidence
The IVD industry needs to be able to bring products to market more quickly than is typical for pharmaceutical products. Innovation cycles are usually shorter, companies do not usually have the budget required for full randomised controlled trials (RCTs), and investors seek return on investment in a relatively short period of time.
The four DECs are collaborating to research and develop new methods to generate the evaluation evidence required by regulators and NHS commissioners in a more effective manner.